In fact, accumulating evidence exists that anti-Ro/SSA-antibodies exert significant electrophysiological effects on the heart via an inhibitory cross-reaction with the extracellular pore region of the hERG-K+ channel (23–27), leading to a higher propensity of developing LQTS (28–31) and VAs/TdP (24, 32, 33) in anti-Ro/SSA-antibody positive adults and newborns subjects. Here, TRIM21 is linked to familial long QT syndrome.